

# Media Release

---

July 1, 2020

## **TOPADUR PHARMA AG Announces Daniel L. Vasella, M.D. as Newly Appointed Board Member**

**Zurich-Schlieren, Switzerland, July 1, 2020.** The shareholders of the company elected today Dr. Daniel L. Vasella, – former CEO and President of NOVARTIS - as new members to the Board of Directors of Topadur Pharma AG.

“I am extremely happy with the election of Dr. Vasella to the Board of Directors. His visionary leadership and his dedication to deliver transformative treatments to help patients is impressive and deeply aligns with our mission. With his medical background he complements the board at the right time when we begin the clinical development with TOP-N53, a promising drug candidate to enable wound healing” said Reto Naef, Chairman of the Board of Directors and CEO at TOPADUR.

### **About Dr. Daniel L. Vasella**

Daniel Vasella, M.D., works as board director, coach and strategic consultant for top executives.

After the foundation of Novartis in 1996 he led the company for 17 years as CEO (1996-2010) and Chairman of the Board of Directors (1999-2013). Since 2013 Dr. Vasella is Honorary Chairman of the Board of Directors for Novartis AG.



Before the Novartis merger, Dr. Vasella was CEO of Sandoz Pharma Ltd. and a member of the Sandoz Group Executive Committee. From 1988 to 1992, he worked for Sandoz Pharmaceuticals Corporation in the United States, prior to which he held a number of medical positions in Switzerland. He graduated with an M.D. from the University of Bern and completed executive training at Harvard Business School. Dr. Vasella also trained as psychoanalyst and executive coach. He was awarded an honorary doctorate from the Faculty of Medicine at the University of Basel and the Harvard Business School Alumnus Award and many other distinctions.



# Media Release

---

Dr. Vasella is a member of the board of directors of PepsiCo, Inc. and the American Express Company and several biotech companies. He is also a foreign honorary member of the American Academy of Arts and Sciences, as well as of various cultural establishments.

Daniel Vasella is married and father of three children.

## About TOPADUR

TOPADUR is a patient-oriented biotech company enhancing quality of life through cutting-edge research. The Swiss based biotech company in Schlieren (Zurich) is developing a new class of therapies based on their innovative Enzyme Regulation System (ERS), targeting high medical needs. TOP-N53 is the lead clinical candidate for diabetic foot ulcer and first drug candidate brought into clinical trial at the beginning of this year. TOPADUR's compounds through the ERS pathway correct the deficit in the cell-cell communication, which can be the cause of chronic wounds resulting from insufficient local blood-circulation.

TOPADUR's R&D portfolio consists of promising development candidates in regenerative medicine, oncology, ophthalmology and medical aesthetics.

For more information regarding TOPADUR PHARMA AG, please go to:

[www.topadur.com](http://www.topadur.com)

## For further information please contact:

Mrs. Dr. Paola Atzei  
Public Relations & Media Contact  
TOPADUR PHARMA AG, Grabenstrasse 11A, CH-8952 Schlieren  
+41 44 755 44 61  
[paola.atzei@topadur.com](mailto:paola.atzei@topadur.com)

## DISCLAIMER

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of TOPADUR PHARMA AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.